All In Biotech

Drug Trial Radar · NCT00918411

A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Jun 2009

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Who can join
Male only, from 20 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore and examine endpoints that allow evaluation of the "clinically significant improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" by this drug in patients with diarrhea-predominant irritable bowel syndrome (IBS).

Conditions

  • Irritable Bowel Syndrome

Interventions

  • RamosetronDrug

    oral

  • PlaceboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IBS severity index (Japanese version)Time frame: 12 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hokkaido, Japan

  • Site not named

    Kansai, Japan

  • Site not named

    Kantou, Japan

  • Site not named

    Kyusyu, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.